logo
Plus   Neg
Share
Email

Novartis: Gilenya Effective Against 4 Measures Of Disease Activity In MS

Swiss drugmaker Novartis AG (NVS) Monday said that two new analyses from the Phase III Transforms study demonstrated how its Gilenya (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis - brain volume loss, lesion activity, relapse rates and disability progression.

Improvements were seen in patients who switched from standard interferon treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study.

MS is a chronic neuroinflammatory and neurodegenerative illness where disease activity leads to accumulation of disability and loss of brain tissue.

The new analysis evaluated the association between measures of disease activity in the first year of therapy and long-term clinical outcomes. Gilenya increased the proportion of patients who were disease-free by almost 50 percent when switched from interferon to Gilenya in year-1 to year-2.

Patients who had disease-activity at the end of the first year were significantly less likely to remain clinically disease free during the following 3.5 years of the extension study.

A separate post-hoc analysis showed that patients who had disease-activity in the year prior to entering the study, despite prior treatment with a disease-modifying treatment, experienced sustained benefit on Gilenya with a lower annualized relapse rate compared to those who were given interferon for
the first year.

The analyses were presented at the 23rd meeting of the European Neurological Society or ENS in
Barcelona.

Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals, said, "Data have consistently shown that treatment with Gilenya leads to more patients staying disease free, compared to standard interferon treatment."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart is ditching its dress code policy and is testing a new dress code that will allows "associates" to wear blue denim and shirts of any solid color. The updated dress coded guidelines now allow employees to wear blue "jeggings" and blue jeans and shirts of any solid color, according to a Walmart... Canadian investment firm Fairfax Financial Holdings Ltd. has submitted a "stalking horse" bid worth C$300 million, or $237 million, for the Canadian unit of Toys "R" Us, according to court documents. A stalking horse bid is an initial bid on the assets of a bankrupt company. The bankrupt company will choose an entity from a pool of bidders who will make the first bid on its assets. The car rental market in the U.S. is consolidating as large car rental companies are buying smaller, local companies to expand their portfolio of premium and value brands. The key players in the U.S. market include Enterprise Holdings, Hertz Global Holding and Avis Budget Group. Let's take a look at some of the best and worst car rental companies in the U.S.
Follow RTT